Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN144,04144,160,72
Msft-0,12
Nokia13,24513,2659,73
IBM0,34
Mercedes-Benz Group AG50,1250,120,72
PFE-0,19
23.05.2026 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 22.05.2026 21:59:16
TEVA PHARMACEUT.INDUSTR.SP-ADR (TEVA.K, NY Consolidated)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
34,05 -0,34 -0,12 46 655 647
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 24.05.2026
Popis společnosti
Obecné informace
Název společnostiTeva Pharmaceutical Indstris Lmtd..(ADR)
TickerTEVA
Kmenové akcie:ADR
RICTEVA.K
ISINUS8816242098
Prioritní akciePreferred Shares
RICTEVVF.PK^L18
Poslední známé roční výsledky31.12.2025
Poslední známé čtvrtletní výsledky31.03.2026
Počet zaměstnanců k 31.12.2025 31 173
Akcie v oběhu k 31.03.20261 164 000 000
MěnaUSD
Kontaktní informace
Ulice124 Dvora Hanevi'a St.
MěstoTEL AVIV-YAFO
PSČ6944020
ZeměIsrael
Kontatní osobaChristopher Stevo
Funkce kontaktní osobySVP - Investor Relations & Competitive Intelligence
Telefon97 239 148 213
Fax97239234050

Business Summary: Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Teva Pharmaceutical Indstris Lmtd..(ADR) revenues increased 2% to $3.98B. Net income applicable to common stockholders increased 72% to $369M. Revenues reflect Other segment increase from $205M to $584M, Europe segment increase of 12% to $1.34B, Other segment increase from $205M to $584M, Europe segment increase of 12% to $1.34B.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Medicinal & Botanical Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Medicinal and Botanical Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICBiological Prod's Not Diagnostic
SICMedicinals And Botanicals
SICCommercial Physical Research
SICDrugs/proprietaries/sundries



  • Poslední aktualizace: 24.05.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorRichard Francis5701.01.202301.01.2023
Chief Financial Officer, Executive Vice PresidentEliyahu Kalif5322.12.201922.12.2019
Executive Vice President, Chief Human Resources OfficerPlacid Jover45
Executive Vice President - European CommercialRichard Daniell5927.11.201727.11.2017
Executive Vice President - U.S. CommercialChristine Fox5817.11.202317.11.2023
Executive Vice President - Global R&D, Chief Medical OfficerEric Hughes56
Executive Vice President - Business DevelopmentEvan Lippman5731.03.202531.03.2025
Executive Vice President - International Markets CommercialMark Sabag5515.08.2021
Executive Vice President - Teva Global OperationsMatthew Shields5203.06.202403.06.2024
Interim Chief Legal OfficerBrian Savage41